BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schreiner J, Thommen DS, Herzig P, Bacac M, Klein C, Roller A, Belousov A, Levitsky V, Savic S, Moersig W, Uhlenbrock F, Heinzelmann-Schwarz VA, Umana P, Pisa P, von Bergwelt-Baildon M, Lardinois D, Müller P, Karanikas V, Zippelius A. Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. Oncoimmunology 2016;5:e1062969. [PMID: 27057429 DOI: 10.1080/2162402X.2015.1062969] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Coeshott C, Vang B, Jones M, Nankervis B. Large-scale expansion and characterization of CD3+ T-cells in the Quantum® Cell Expansion System. J Transl Med 2019;17:258. [PMID: 31391068 DOI: 10.1186/s12967-019-2001-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
2 Walseng E, Nelson CG, Qi J, Nanna AR, Roush WR, Goswami RK, Sinha SC, Burke TR Jr, Rader C. Chemically Programmed Bispecific Antibodies in Diabody Format. J Biol Chem 2016;291:19661-73. [PMID: 27445334 DOI: 10.1074/jbc.M116.745588] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
3 Li H, Er Saw P, Song E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol Immunol 2020;17:451-61. [PMID: 32313210 DOI: 10.1038/s41423-020-0417-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
4 Xu G, Luo Y, Wang H, Wang Y, Liu B, Wei J. Therapeutic bispecific antibodies against intracellular tumor antigens. Cancer Lett 2022;:215699. [PMID: 35487312 DOI: 10.1016/j.canlet.2022.215699] [Reference Citation Analysis]
5 Yang F, Wen W, Qin W. Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies. Int J Mol Sci 2016;18:E48. [PMID: 28036020 DOI: 10.3390/ijms18010048] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
6 Qi J, Hymel D, Nelson CG, Burke TR Jr, Rader C. Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1. Front Immunol 2019;10:1994. [PMID: 31497024 DOI: 10.3389/fimmu.2019.01994] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
7 Thommen DS, Schumacher TN. T Cell Dysfunction in Cancer. Cancer Cell 2018;33:547-62. [PMID: 29634943 DOI: 10.1016/j.ccell.2018.03.012] [Cited by in Crossref: 305] [Cited by in F6Publishing: 307] [Article Influence: 101.7] [Reference Citation Analysis]
8 Kobold S, Pantelyushin S, Rataj F, Vom Berg J. Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. Front Oncol 2018;8:285. [PMID: 30090763 DOI: 10.3389/fonc.2018.00285] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
9 Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, Savic Prince S, Wiese M, Lardinois D, Ho PC, Klein C, Karanikas V, Mertz KD, Schumacher TN, Zippelius A. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med 2018;24:994-1004. [PMID: 29892065 DOI: 10.1038/s41591-018-0057-z] [Cited by in Crossref: 322] [Cited by in F6Publishing: 324] [Article Influence: 80.5] [Reference Citation Analysis]
10 Iwahori K, Shintani Y, Funaki S, Yamamoto Y, Matsumoto M, Yoshida T, Morimoto-Okazawa A, Kawashima A, Sato E, Gottschalk S, Okumura M, Kumanogoh A, Wada H. Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment. Sci Rep 2019;9:2636. [PMID: 30796310 DOI: 10.1038/s41598-019-39345-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
11 Trüb M, Uhlenbrock F, Claus C, Herzig P, Thelen M, Karanikas V, Bacac M, Amann M, Albrecht R, Ferrara-Koller C, Thommen D, Rothschield S, Savic Prince S, Mertz KD, Cathomas G, Rosenberg R, Heinzelmann-Schwarz V, Wiese M, Lardinois D, Umana P, Klein C, Laubli H, Kashyap AS, Zippelius A. Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer. J Immunother Cancer 2020;8:e000238. [PMID: 32616554 DOI: 10.1136/jitc-2019-000238] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
12 Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, Nicolini V, Perro M, Nayak T, Bommer E, Schoenle A, Karagianni M, Le Clech M, Steinhoff N, Klein C, Umaña P, Bacac M. Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity. Front Oncol 2020;10:575737. [PMID: 33330050 DOI: 10.3389/fonc.2020.575737] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
13 Kamakura D, Asano R, Yasunaga M. T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. Pharmaceuticals (Basel) 2021;14:1172. [PMID: 34832954 DOI: 10.3390/ph14111172] [Reference Citation Analysis]
14 Noguchi Y, Yamamoto Y, Iwahori K, Matsumoto M, Hirata M, Okuyama H, Shintani Y, Kumanogoh A, Wada H. Tetracyclines Enhance Anti-tumor T-Cell Responses Induced by a Bispecific T-Cell Engager. Biological & Pharmaceutical Bulletin 2022;45:429-37. [DOI: 10.1248/bpb.b21-00806] [Reference Citation Analysis]
15 Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, van Hall T. Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors. Cancers (Basel) 2021;13:287. [PMID: 33466732 DOI: 10.3390/cancers13020287] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
16 O'Brien SM, Klampatsa A, Thompson JC, Martinez MC, Hwang WT, Rao AS, Standalick JE, Kim S, Cantu E, Litzky LA, Singhal S, Eruslanov EB, Moon EK, Albelda SM. Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer. Cancer Immunol Res 2019;7:896-909. [PMID: 31053597 DOI: 10.1158/2326-6066.CIR-18-0713] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]